[New antiarrhythmic drugs for therapy of atrial fibrillation: II. Non-ion channel blockers].
The therapeutic approach to atrial fibrillation is difficult and challenging. The effect of "classical" antiarrhythmic agents is based on their inhibitory effects on various ion channels. However, therapeutic benefit of these agents is often limited. The primary goal of this article is to discuss new therapeutic approaches using non-ion channel blocking drugs in the treatment of atrial fibrillation. Some of the substances discussed in this article have been used already in the clinical practice. Others, for example gentherapeutic approaches, are still in the experimental state. In contrast to ion channel blocking agents their efficacy is based on the suppression of structural remodeling. Hence, it can be assumed that due to these effects they may also be beneficial in the primary prevention of atrial fibrillation.
Hammwöhner
M
M
Otto-von-Guericke Universitätsklinik Magdeburg, Klinik für Kardiologie, Angiologie und Pneumologie, Leipzigerstr. 44, 39120, Magdeburg, Germany.
D'Alessandro
A
A
Dobrev
D
D
Kirchhof
P
P
Goette
A
A
D000804:Angiotensin II / Q000008:administration & dosage*; D000818:Animals; D000889:Anti-Arrhythmia Agents / Q000008:administration & dosage*; D001281:Atrial Fibrillation / Q000188:drug therapy* / Q000503:physiopathology*; D002121:Calcium Channel Blockers / Q000008:administration & dosage; D015316:Genetic Therapy / Q000379:methods; D006329:Heart Conduction System / Q000187:drug effects / Q000503:physiopathology*; D006801:Humans; D008955:Models, Cardiovascular; D017410:Practice Guidelines as Topic; D010818:Practice Patterns, Physicians'; D016896:Treatment Outcome
D000889:Anti-Arrhythmia Agents; D002121:Calcium Channel Blockers; D000804:Angiotensin II